Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A landmark phase 3 trial found that stereotactic radiosurgery (SRS) is a viable alternative to whole-brain radiotherapy for small cell lung cancer brain metastases. While SRS didn't outperform on cognitive outcomes, patients lived nearly 9 months longer on average. Experts say treatment should still be individualized based on disease burden and patient age.
For decades, whole-brain radiotherapy (WBRT) was the go-to treatment for brain metastases in small cell lung cancer (SCLC) patients — partly out of fear that skipping it would let the disease spread unchecked. Now, the first randomized phase 3 trial comparing stereotactic radiosurgery (SRS) to modern, cognition-sparing WBRT is challenging that assumption.
The NRG-CC009 trial enrolled 151 SCLC patients with brain metastases and randomized them to SRS or hippocampal-avoidant WBRT plus memantine. While SRS didn't beat WBRT on the primary endpoint of cognitive preservation, it was linked to a striking survival advantage — nearly double the median overall survival. Experts at ASTRO 2026 urged caution in over-interpreting the survival data, since the trial wasn't powered for that outcome, but called the findings a meaningful step forward.
By the Numbers:
Why it matters: SRS is already standard for brain mets in many other cancers — SCLC patients were largely left out of earlier trials. These results open the door to a more targeted approach, especially for patients with limited brain disease or those over 60, where whole-brain radiation risks may outweigh the benefits.
